BRIEF published on 10/10/2025 at 22:16, 11 months 16 days ago FDA Approves UZEDY for Bipolar I Disorder in Adults FDA Approval Mental Health Treatment UZEDY Bipolar I Disorder Risperidone
PRESS RELEASE published on 10/10/2025 at 22:11, 11 months 16 days ago Informations privilégiées / Autres communiqués La FDA approuve l’extension d’indication de UZEDY® pour le traitement de patients atteints de trouble bipolaire de type I par Teva Pharmaceuticals et Medincell FDA Medincell Teva Pharmaceuticals UZEDY Traitement Bipolaire
PRESS RELEASE published on 10/10/2025 at 22:11, 11 months 16 days ago Inside Information / Other news releases FDA approves UZEDY as extended-release injectable suspension for bipolar I disorder treatment in adults. Teva and Medincell collaborate on this significant advancement in neuroscience FDA Medincell Teva UZEDY Bipolar I Disorder
BRIEF published on 09/17/2025 at 14:05, 1 year ago Medincell et Teva présentent les données de phase 3 sur l'olanzapine LAI Essai De Phase 3 Traitement De La Schizophrénie Medincell Teva Olanzapine LAI
BRIEF published on 09/17/2025 at 14:05, 1 year ago Medincell and Teva Present Phase 3 Olanzapine LAI Data Phase 3 Trial Schizophrenia Treatment Medincell Teva Olanzapine LAI
PRESS RELEASE published on 09/17/2025 at 14:00, 1 year ago Inside Information / Other news releases Medincell and Teva to discuss Phase 3 Olanzapine LAI data from SOLARIS Trial at 2025 Psych Congress. Webcast details available on Teva's IR website Phase 3 Medincell Teva SOLARIS Trial Olanzapine LAI
PRESS RELEASE published on 09/17/2025 at 14:00, 1 year ago Informations privilégiées / Autres communiqués Teva et Medincell présenteront les résultats de phase 3 de l'Olanzapine LAI à Psych Congress 2025, préparant le lancement du traitement de la schizophrénie avec Teva Schizophrénie Phase 3 Medincell Teva Olanzapine LAI
BRIEF published on 09/12/2025 at 07:35, 1 year ago Medincell Appoints Three New Board Members Innovation Biopharmaceutical Leadership Board Appointments Medincell
BRIEF published on 09/12/2025 at 07:35, 1 year ago Medincell nomme trois nouveaux membres au conseil d'administration Innovation Biopharmaceutique Direction Nominations Au Conseil D'administration Medincell
PRESS RELEASE published on 09/12/2025 at 07:30, 1 year ago Inside Information / Other news releases Medincell appoints Dr. Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon to its Board of Directors, adding valuable expertise in biotech and pharmaceutical sectors Board Of Directors Medincell Dr. Sharon Mates Dr. Charles Kunsch Dr. Pascal Touchon
Published on 09/26/2026 at 01:00, 1 day 18 hours ago Findev Inc. Provides Update on Victoria Park Loan Exposure and Expected Accounting Impairment
Published on 09/25/2026 at 22:15, 1 day 21 hours ago Rocky Shore Gold Closes First Tranche of Non-Brokered Private Placement
Published on 09/25/2026 at 17:30, 2 days 2 hours ago Goldcliff Announces Unit and Flow Through "LIFE" Offerings
Published on 09/25/2026 at 15:00, 2 days 4 hours ago HM Exploration Provides Program Update for the Lewis Pilley's Project
Published on 09/27/2026 at 17:05, 2 hours 38 minutes ago Saudi Tourism Authority Concludes Monaco Yacht Show 2026 with Major Milestones for Saudi Red Sea Yachting
Published on 09/26/2026 at 15:30, 1 day 4 hours ago QUORRA X5 fait ses débuts mondiaux à REHACARE International 2026 en Allemagne
Published on 09/26/2026 at 15:30, 1 day 4 hours ago QUORRA X5 Makes Its Global Debut at REHACARE International 2026 in Germany
Published on 09/26/2026 at 15:15, 1 day 4 hours ago Timur Turlov Elected FIDE President, Becomes First Kazakh to Lead World Chess
Published on 09/26/2026 at 07:45, 1 day 11 hours ago Green SM Begins Pilot Operations In The Netherlands, Further Expanding Its Presence In Europe
Published on 09/25/2026 at 17:45, 2 days 1 hour ago COGRA : ASSEMBLÉE GÉNÉRALE MIXTE DU 16 OCTOBRE 2026 / MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025/2026
Published on 09/25/2026 at 17:40, 2 days 2 hours ago Availability of the 2026 half-year financial report
